아베마시클립
|
|
아베마시클립 속성
- 끓는 점
- 689.3±65.0 °C(Predicted)
- 밀도
- 1.32±0.1 g/cm3(Predicted)
- 저장 조건
- 4°C, protect from light
- 용해도
- insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 산도 계수 (pKa)
- 7.69±0.10(Predicted)
- InChIKey
- UZWDCWONPYILKI-UHFFFAOYSA-N
- SMILES
- C1(NC2=NC=C(CN3CCN(CC)CC3)C=C2)=NC=C(F)C(C2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
아베마시클립 C화학적 특성, 용도, 생산
Characteristics
Class: serine/threonine protein kinaseTreatment: Breast cancer
Oral bioavailability = 46%
Elimination half-life = 18 h
Protein binding = 95–98%
Biochem/physiol Actions
LY2835219 (abemaciclib) was identified via compound and biochemical screening by scientists at Eli Lilly and Company Research Laboratories and selected for its biological activity and highly selective inhibition of the complexes CDK4/ cyclin D1 (IC50 =2 nmol/L) and CDK6/cyclin D1 (IC50 =10 nmol/L), with no activity against other CDK/cyclin complexes or cell-cycle-related kinases within the nanomolar ranges, except for inhibition of CDK9 at IC50 at least five times higher. The compound was shown to act as a competitive inhibitor of the ATP-binding domain of the CDK4 and CDK6 and to be 14 times more potent against CDK4 than against CDK6. In comparison to palbociclib and ribociclib, abemaciclib shows higher selectivity for the complex CDK4/cyclin D1, with IC50 values five times lower than those of the two other compounds[1].효소 저해제
This oral cell cycle inhibitor (FWfree-base = 506.61 g/mol; FWmesylate-salt = 602.70 g/mol; CAS 1231930-82-7 (mesylate salt) ), also known as LY2835219 and N-[5-[ (4-ethyl-1-piperazinyl) methyl]-2-pyridinyl]-5- fluoro-4-[4-fluoro-2-methyl-1- (1-methylethyl) -1H-benzimidazol-6-yl]-2- pyrimidinamine, targets the cyclin-dependent kinase CDK4, or cyclin D1 (IC50 = 2 nM) and CDK6, or cyclin D3 (IC50 = 6 nM), inhibiting retinoblastoma (Rb) protein phosphorylation in early G1, thereby arresting the cell cycle in the G1, suppressing DNA synthesis, and inhibiting cancer cell growth. LY2835219 inhibits activation of AKT and ERK, but not mTOR.아베마시클립 준비 용품 및 원자재
원자재
EthaniMidaMide,N-(4-broMo-2,6-디플루오로페닐)-N'-(1-메틸에틸)-
4-Bromo-2,6-difluoroaniline
2-Bromopyridine-5-carbaldehyde
피페라진,1-[(6-브로모-3-피리디닐)메틸]-4-에틸-
N-이소프로필아세트아미드
1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)-
1H-BenziMidazole, 4-fluoro-2-Methyl-1-(1-Methylethyl)-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-
4-아미노-3,5-디플루오로아세토페논
5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
에틸피페라진(노르말)
디플르오르아닐린(2,6-)
준비 용품
아베마시클립 공급 업체
글로벌( 274)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Beijing Hope Pharmaceutical Co., Ltd. | +86-010-67886402 +8613611125266 |
market@hopelife.cn | China | 71 | 58 |
| Arizest(Shanghai)Pharmatech Co., Ltd | +86-021-60753300 |
3652837972@qq.com | China | 220 | 58 |
| Hebei Yanxi Chemical Co., Ltd. | +8617531190177 |
peter@yan-xi.com | China | 6011 | 58 |
| shandong perfect biotechnology co.ltd | +86-53169958659; +8618596095638 |
sales@sdperfect.com | China | 294 | 58 |
| Henan Bao Enluo International TradeCo.，LTD | +86-17331933971 +86-17331933971 |
deasea125996@gmail.com | China | 2503 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21687 | 55 |
| Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9338 | 55 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32715 | 60 |
| career henan chemical co | +86-0371-86658258 |
sales@coreychem.com | China | 29914 | 58 |
| Biochempartner | 0086-13720134139 |
candy@biochempartner.com | CHINA | 967 | 58 |